Podcasts about Alexion

We're in Copenhagen

Alexion, AstraZeneca Rare Disease, and DHL Express has announced a landmark partnership in a bid to reduce greenhouse gas emissions (GHG) from the air freight of highly specialised medicines manufactured in Ireland. Alexion is the first company in Ireland to sign up to a 100% switch from traditional aviation fuel to sustainable aviation fuel (SAF). This alternative fuel will reduce GHG emissions by over 80% on average compared to traditional aviation fuel. The greener fuel will be switched on all European air freight shipments across 19 European countries. Provided through the DHL GoGreen Plus service, SAF is used as a substitute to conventional fuel and can readily be used as a drop-in replacement in aircraft without the need for modifications to aircraft engines. Produced from waste and residue-based feedstock, such as used cooking oil, SAF has improved sustainability compared to traditional fossil jet fuel which is primarily derived from crude oil. Reducing the GHG emissions associated with the transport of medicinal products is an important part of AstraZeneca's wider sustainability strategy. This includes a focus on partnerships across the healthcare sector including supply chain decarbonisation. From 2030, the aim is to halve the entire value chain footprint (absolute Scope 3 GHG emissions), from a 2019 base year, on the way to becoming science-based net zero by 2045. Sylvia Kiely, Vice President, Global Supply Chain and Product Strategy Lead, Alexion, AstraZeneca Rare Disease said: "Moving our air freight to Sustainable Aviation Fuel is an important milestone in reaching our Scope 3 targets, with the ambition of being science-based net zero by 2045. Through our partnership with DHL Express we've signed up immediately to a 100% change in fuel, rather than scaling up over time, which demonstrates how seriously we take environmental stewardship." Brian Murray, Commercial & Same Day Director, DHL Express Ireland said: "We are thrilled to partner with Alexion. Our GoGreen Plus service using emission-reduced Sustainable Aviation Fuel demonstrates the tangible impact of collaborative efforts to decarbonise the logistics industry and support our customers in achieving their sustainability goals. This initiative aligns perfectly with DHL's sustainability strategy and our goal to achieve net-zero emissions by 2050." Countries receiving the medicines under the GoGreen Plus service include Austria, Belgium, Denmark, Estonia, Finland, France, Georgia, Germany, Guernsey, Iceland, Ireland, Italy, Luxemburg, Netherlands, Norway, Portugal, Spain, Sweden and United Kingdom. See more stories here.

We saw more action on the M&A front this week as Novartisbought back its blood thinner abelacimab and the rest of Anthos Therapeutics for up to $3.1 billion and still ahead, a potential buyout of SpringWorks Therapeutics by Merck KGaA, which confirmed it's in “advanced discussions” with the biotech. Meanwhile, Eli Lilly signed aglobal licensing deal for a MASH asset with South Korea's OliX Pharmaceuticals.As Q4 and full-year 2024 earnings continue to roll in, BMS, Eli Lilly,Novo Nordisk, AstraZeneca, Eisai, Vertex and Gilead all reported their results in the past week. Notably, BMS continues to reorganize, now targeting an additional $2 billion in savings through 2027, and AstraZeneca axed two rare disease drugs from its $39 billion acquisition of Alexion. When it comes to revenue growth, Novo's Wegovy and Lilly's Zepbound continue to climb at a striking pace—a phenomenon that has at times driven the weight loss drugs into shortage and spawning a controversialshadow market of off-brand versions.Speaking of controversy, Regeneron is suing its Dupixent partner Sanofi, claiming the French pharma has failed to provide it with adequate information regarding sales of the blockbuster anti-inflammatory drug—which missed analyst expectations in Q4.On the clinical side, the pulmonary fibrosis space continues to see positive results, with Boehringer Ingelheim notching its second Phase III win in six months for nerandomilast. It wasn't all good news, however, as Pliant Therapeutics suspended dosing and enrollment in a Phase IIb/III study of its idiopathic pulmonary fibrosis candidate, causing its stock to crash.Finally, BioSpace released a special edition of ClinicaSpace this week focused on the resurgent cardiovascular space—just in time for Valentine's Day! Sign uphere to receive your copy.

'One FM' by One MSL strives to connect voices within the global Field Medical community.For episode 3 Helen was joined by Kate Bradford, Global Head of Medical Training & Field Capabilities at Alexion.If you would like to feature on a future episode, please email community@onemsl.comhttps://www.onemsl.com/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eisai reports lagging sales of Leqembi in the US and is now looking towards gaining approval for a subcutaneous version. Novo Nordisk executives are trying to boost sentiment after the failure of obesity candidate Cagrisema, without providing hard numbers. Regeneron is suing Sanofi for allegedly withholding information about the sales of Dupixent. Nasdaq newcomers Acelyrin and Alumis have merged to focus on immune-mediated diseases. The AAPS National Biotechnology Conference will cover trends in research and biopharma markets.Equillium's Itolizumab is competing with Humira in ulcerative colitis. FDA approval of Vertex's non-opioid Jornavx signals a new era in pain treatment. Novo's bispecific for hemophilia has aced a phase III pediatric trial. Lilly has increased Zepbound supply, prompting analysts to question if it is sustainable. BMS has added $2 billion to cost-cutting plans and is eyeing deals after the success of Cobenfy. AstraZeneca has axed two Alexion assets as Q4 earnings exceed expectations.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly CEO David Ricks faced questions about potential oversupply of the company's drug Zepbound. Analysts are concerned that Lilly may have gone too far in expanding the supply chain for its GLP-1 drug. Meanwhile, Bristol Myers Squibb announced plans to increase cost-cutting measures and pursue new deals following the success of its drug Cobenfy. AstraZeneca discontinued two assets acquired from Alexion, despite exceeding Q4 earnings expectations. BMS reported $10 million in sales for Cobenfy in the fourth quarter of 2024.On the other hand, the AAPS National Biotechnology Conference will take place in May, covering trends in research and biopharma markets. X4 Pharmaceuticals and Viracta faced financial struggles, while Kura Oncology eyes FDA filing after a win in AML. Frontier Medicines announced staff cuts, but there is optimism for the job market in January. Pfizer is in discussions for new deals, including potential collaborations in China.Overall, job opportunities are available at companies like Amgen, Takeda, and Novo Nordisk.

Mixshows every weekend on DanceMixUSA.com, NoFearRadio.com CARDIO Dance Radio, Mix93FM.com, KCIE 90.5, WDA1.com, and RadioFreeNashville.org.1- Laura van Dam X P.O.U ft. Jamie Lee Harrison - Rule The World2- X.Guardians - Adam Genesys3- Walter Armand - In Your Mind (MariaFila Remix)4- Flashmob, Oxylion & Danger - Serious5- Azooland - House Of Future6- Basura Boyz & Avilo - Backseat (Mancodex Extended Remix)7- Öwnboss, Deadline ft. Luisah - Miracle 8- Alexion & JD Farrell - Illusive Thoughts9- GENESI x Laherte - Pleasure 10- HATTRICK - Ether11- Alka - Mindwaves 12- Lost Prince, Higher Lane, Hi Motive - Lost It 13- Different Stage & Jas. - Lotus (Hear Me Out)

Omkring 2000 personer lever i Danmark med den sjældne genetiske sygdom Neurofibromatose 1 (NF1), der både kan nedarves fra forældrene eller vise sig som en nyopstået mutation. 29-årige Sofie lever med den sjældne gen-sygdom NF1, der blandt andet giver hende en skæv ryg. Da Sofie gik i anden klasse, var ryggen 95 grader skæv og Sofie har gennem sin opvækst været igennem ni rygoperationer for at rette op på den. Sofie lever i dag et godt liv med sygdommen og arbejder dagligt for at hjælpe andre med NF1.Podcasten er produceret af SundhedsTVAfsnitet er sponsoreret af Alexion.

In this inspiring episode of It Happened To Me, hosts Cathy and Beth sit down with Alex Brito, a remarkable advocate in the rare disease community and one of the first 100 individuals diagnosed with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare neurological disease that affects an estimated 6,000 Americans, causing severe and unpredictable relapses that can lead to vision loss, chronic pain, and paralysis. Alex shares her journey, from the challenges of misdiagnosis and temporary paralysis to her empowering outlook on life with NMOSD—she affectionately refers to the condition as “her bestie.” Alex's dedication to advocating for individuals with disabilities is evident in her work teaching adaptive technology to those with vision loss. Her incredible resilience is matched by her active lifestyle, which includes powerlifting and earning the distinction of being the first blind woman to achieve a yellow belt in Krav Maga. Listeners will also learn about Alexion's short film, Rare Connections in NMOSD (Accessible Version), which highlights Alex's story and helps raise awareness about this rare disease. Key Takeaways: What is NMOSD, its symptoms, and the challenges in diagnosing this rare condition. Alex's personal journey with NMOSD, including vision loss, paralysis, and finding strength in adversity. The importance of adaptive technology and how Alex empowers individuals with vision loss. Alex's inspiring accomplishments as a powerlifter and martial artist. Insights into Alexion's short film Rare Connections in NMOSD and its impact on awareness and advocacy. Resources Mentioned in This Episode: Watch Alexion's short film, Rare Connections in NMOSD here Alex mentioned using JAWS, a screen reading program for those with vision difficulties Support organizations for NMOSD that Alex recommends in the episode are The Guthy-Jackson Foundation and The Sumaria Foundation Learn more about NMOSD through the organization NMOSD Won't Stop Me  Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

In this episode, our guest, Tamar (Tay-mar) Thompson with us, the Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease. With over 20 years of experience in healthcare, Tamar leads global corporate efforts in policy and advocacy. She recently has been showcasing Alexion's new short film, Rare Connections in NMOSD where she underscores the need to raise awareness of NMOSD, a rare neurological disease, to help reduce the time to diagnosis and advance care. A dedicated advocate for health equity, Tamar continues to highlight the unmet needs of the rare disease community.TopicsNeuromyelitis optica spectrum disorder (NMOSD): diagnosis, prevalence/incidence, overview of symptoms, and why it's so important to raise awareness of rare diseasesRare Connections in NMOSD and why Alexion created this first-of-its-kind short filmWhat Alexion is doing to help improve equity and health outcomes for people living with rare diseasesUnveiling Connections: The Story Behind Alexion's Groundbreaking Film on NMOSD• Bridging the Gap: Confronting the Diagnostic and Care Challenges in Rare Diseases• Left Behind: Addressing Health Equity for the Rare Disease Community• Global Voices: How Alexion Shapes Policy to Transform Rare Disease Care• Driven by Purpose: Alexion's Journey to Champion Rare Disease AdvocacyGuest - Tamar ThompsonLinkedIn: - https://www.linkedin.com/company/alexion-pharmaceuticals/- https://www.linkedin.com/in/tamarthompson/Facebook: https://www.facebook.com/AlexionPharmaceuticalsInc/Twitter/X: https://x.com/alexionpharma?lang=eYouTubehttps://www.youtube.com/@alexionpharmaceuticalsinc.3357Rare Connections Film: https://youtu.be/cfnE7cxfY3s?si=zozSq2NZK8kb2i6kRare Connections Film (Accessible Version): https://youtu.be/dwKpZQSZuZ0?si=77UN5QaRJNuM2rnmHost - Hillary Blackburn, PharmD, MBAwww.hillaryblackburn.comhttps://www.linkedin.com/in/hillary-blackburn-67a92421/ @talktoyourpharmacist for Instagram and Facebook ★ Support this podcast on Patreon ★

Follow Alexion on X Here! Follow Alexion on Twitch Here! Subscribe to Alexion's Youtube channel Here! Want more FUT Ballerz? Support the show by signing up for Ad Free and Bonus Pods Sign Up Here Want to get involved with the hosts and FUT Ballerz Community? Join our FREE Discord server Here! Have a question for the show? You can reach us in the discord, on social media (links below) or on our website! Visit our friends at FIFAUTEAM! Follow us on X. Hunter Paul Wyse Matt FUT Ballerz FIFAUTEAM Follow us on TikTok FUT Ballerz WyseFIFA Follow us on Twitch FUT Ballerz Paul Follow us on Youtube FUT Ballerz WyseFIFA Learn more about your ad choices. Visit podcastchoices.com/adchoices

ElectroNic Sessions Podcast Ep. 083 Is now available Via Podcast, Featuring a very special guest mix and it is our pleasure to have the first female dj on our show! Please give it up for Plasmatique! Presenting her new showcase selection, Enjoy! -------------Playlist-------------- 01. Plasmatique - Perpetuity  02. Stephan Bodzin, Jem Cooke, Massano - Healing  03. Alexion & Coff - Falling Into Oblivion  04. Rebuke - Along Came Polly - (Konstantin Sibold, ZAC, CARMEE Remix) 05. Thomas Helmich - Spectre 06. Armin van Buuren, Sharon Den Adel - In And Out Of Love(Innellea Remix) 07. Christian Corsi - Aether 08. Max & Dana - Seventh Day  09. Thomas Helmich - Hedonism 10. ARIAMS, Farnoodex, Audrie Minds - Illusion  11. Plasmatique - Mandala 12. John Summit, HAYLA - Shiver (Cassian Remix) 13. ARTBAT, Rokston, Avalan, AVALAN ROKSTON - The Ocean 14. Plasmatique - Tuvan  

Alexion, AstraZeneca Rare Disease and DHL Global Forwarding Freight today announced a new partnership to commence Ireland's first sustainable fuel deliveries using Hydrogenated Vegetable Oil (HVO) for the pharmaceutical industry. By converting to HVO fuel, the two companies are aiming to reduce annual Greenhouse Gas (GHG) from road freight by up to 90% compared to GHG emissions associated with deliveries using diesel. The partners have identified multiple transport routes within Ireland, Northern Ireland, and Europe, which will all convert from diesel to HVO to deliver medicines manufactured in Alexion's sites in Athlone and Blanchardstown, Dublin. HVO will be used in DHL's vehicles on more than 500 deliveries, on an annual basis to 10 countries. Produced from biomass such as used cooking oils and waste from food manufacture, HVO is a drop-in fuel, meaning it can be used within existing vehicles without compromising operational performance, removing the need for new infrastructure or fleet. Reducing the GHG emissions associated with the transport of medicinal products is an important part of AstraZeneca's wider sustainability strategy. This includes a focus on partnerships across the healthcare sector to accelerate the delivery of net-zero health systems, including supply chain decarbonisation. AstraZeneca has set a target to reduce absolute Scope 1 and Scope 2 GHG emissions by 98% from 2015 base year.[i] From 2030, the aim is to halve the entire value chain footprint (absolute Scope 3 GHG emissions), from a 2019 base year, on the way to becoming science-based net zero by 2045. Sylvia Kiely Vice President - Global Supply Chain and Product Strategy Lead, Alexion AstraZeneca Rare Disease said: "Today's announcement with DHL to move from Diesel to HVO fuel is another milestone in our commitment to reducing our environmental impact, and dependency on fossil fuels within our global supply chain in relation to Scope 3. By working with our partners to extend eco-conscious practices to our full freight network, we can further minimise our environmental impact and dependency on fossil fuels within our global supply chain." Maurice Meade, Managing Director of DHL Global Forwarding Freight, Ireland, said: "This is another step in the right direction as we strive to run more sustainable operations for our customers that reduce the inherent Greenhouse emissions in transporting goods. We are delighted to see Alexion be one of the trailblazers to make this significant switch in approach and thereby follow-up on their sustainability goals with clear actions. This initiative perfectly aligns with our sustainability strategy at DHL Group, whereby our aim is to reduce all logistics-related emissions to net-zero by 2050." See more stories here.

Follow me: Facebook: fb.me/xabionly Twitter: twitter.com/xabionly Youtube: youtube.com/xabionly Mixcloud: mixcloud.com/xabionly Instagram: instagram.com/xabionly TRACKLIST: https://1001.tl/25f5vt9t Spotify playlist: https://open.spotify.com/playlist/4STV7DPVgwI4ntvi1sQvjh?si=CU6lCNZcRkKiZytdXaI5TQ TRACKLIST: 01. Kevin de Vries & Y do I - Saga [AFTERLIFE] 02. Stephan Dodevsky - Bellum [LIMINAL] 03. Alexion, Thomas Helmich - Serpentis [QUANTUM FEELS] 04. Stephan Dodevsky - Undisclosed [LIMINAL] 05. Bigfett - Takatum [MAHOOL] 06. Alexion, COFF - Back to Life [QUANTUM FEELS] 07. Jos & Eli - Starlit [SIAMESE] 08. Diego Miranda & Mëlbëc - Damaru [DHARMA] 09. Armin van Buuren - Pulstar [ARMIND] [RELEASE OF THE WEEK] 10. Kosling & LUX - Higher [PROTOCOL] 11. Larza & Newman ft. Tobias Ward - Begging You [EUPHONIX] 12. 3Beat - Baby [NO DEFINITION] 13. Fisher & Flowdan - Boost Up (Kriss Reeve Remix) 14. Dirty Signal, Jake Ryan & Jean Rodz - Background [CLUBWRK] 15. DJ Yasmin & HΛNNΛH X - Clap Anthem [REVEALED RADAR] 16. Ship Wrek ft. Sarah de Warren - Headrush [ARMADA] 17. Giorgia Angiuli - Nietzsche [ARMADA] 18. Father 808 - Mortality [REVEALED] [PROMO OF THE WEEK] 19. Luca Testa & Lotus - Wonderful Life [SMASH THE HOUSE] 20. Dimitri Vegas & Like Mike - Heroine [SMASH THE HOUSE] [TRACK OF THE WEEK] 21. W&W & Harris & Ford & Special D - Another Day In Paradise [RAVE CULTURE]

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering: The epidemiological challenge of rare diseases and representing the topic at the White House Why is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements? The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZeneca Some top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your champions Tamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion's charitable foundation and the Alexion lead for Inclusion and Diversity.  Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors. Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease. Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases.

MauLr on Radio Tracklist #723 Mixed by DJ MauLr Yero feat. Christian Burns - Wonderful Life (Kryder's Guilty Pleasure Mix) Naffe - I Don't Need Love Black Box x Alexion x Irajá - Alright (Abstraal Rework) York feat. Ava Silver - On Your Mind (Mark's Special) Flamez Nguyen & Naze - Move That Jonas Blue, Zoe Wees - Mountains (Eden Prince Remix) Nicky Romero & Third Party - Bad Boy NOTSOBAD & Able Faces - Hollow Ground NØSVN & WINARTA feat. David Allen - Lost In Midnight Allan Biggs - Keep It On The Low Sander van Doorn - Unite (feat. Eke) Samlight, NickyB ft. Robin Vane - On To Tomorrow Malóne, Jesse Bravo - Beef The Pressure & Trance Wax - Nothing's Gonna Hurt You Baby

Jointly Provided by American Academy of CME and CheckRare CE.Supported by educational grants from argenx US, Inc. and UCB Inc.To claim credit for this program, please visit https://checkrare.com/learning/p-myasthenia-gravis-research-highlights-aan-2024/Estimated time to complete: 0.5 hoursStart date: June 15, 2024End date: June 30,2025Activity DescriptionThis accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.Treatment of myastheniagravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient's comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as well as real world data, were presented at the American Academy of Neurology Annual Meeting (AAN 2024) held in Denver, CO.This CME activity, hosted by Nicholas Silvestri, MD, of the University of Buffalo, provides an overview of the latest clinical research presented at AAN 2024 focused on myasthenia gravis.Activity FacultyNicholas Silvestri, MDProfessor of NeurologyUniversity of Buffalo Jacobs School of Medicine and Biomedical SciencesTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology, and general practice. Other members of the care team may also participate.Learning ObjectiveAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage people with myasthenia gravis and its clinical relevanceAccreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Silvestri discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: argenx, Alexion, UCB, Immunovant, Janssen, AmgenSpeakers Bureau: argenx, Alexion, UCB, TakedaPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. American Academy of CME and CheckRare CE. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older. To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.01:07-04:26: Background on Dr Dana Vigier04:26-07:07: What is myasthenia gravis?07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?09:43-11:33: How effective are current treatments for myasthenia gravis?11:33-12:56: Do all the myasthenia gravis drugs work in the same way?  12:56-18:35: What R&D is taking place in myasthenia gravis?18:35-21:14: Alexion and its work on myasthenia gravis21:14-22:01: Myasthenia gravis clinical trials22:01-23:58: The importance of myasthenia gravis awareness month23:58-25:31: Would early diagnosis make a difference?25:31-27:54: Transformation through new treatmentsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Join us for an enchanting interview with Singer-songwriter Alex Alexion as she shares insights into her upcoming single "Hold Out Hope"

William A. Lumpkin (Will) is a devoted husband to Layla, a proud father to Ailey, Sage, and Liam, and a purpose-driven leader with a passion for delivering significant impact through high-performing teams. Will serves as Vice President of Sales at Agios Pharmaceuticals in Cambridge, MA, where he leads a team dedicated to providing disease education and access to first and best-in-class solutions for underserved patient populations affected by chronic hemolytic anemia. Prior to Agios, William was Head of New Product Strategy and Business Development at Alexion Pharmaceuticals, Chief of Staff to the Chief Commercial and Global Operations Officer, and the Commercial Integration lead for Alexion into Astra Zeneca rare disease. His innovative solutions earned him Guiding Star and Excellence Awards. With a diverse background spanning leadership across functional disciplines, including finance, sales, marketing, and strategy, at Baxter, Baxalta, Shire, and Takeda, Will has demonstrated his ability to build and lead teams that operate with a sense of urgency in service of others. His professional journey began in finance at Procter & Gamble and includes time as a lecturer at UNC Kenan Flagler School of Business. Will holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science in Finance from Indiana University, where he excelled as a four-time letterman, senior captain of the Hoosier football team, and President of the Alpha Chapter, Kappa Alpha Psi Fraternity, Inc. Originally from Dayton, Ohio, Will and his family reside in Houston, where he remains actively engaged in community leadership roles, including serving on the Hermann Park Conservatory Board and as a Senior Fellow at the American Leadership Forum. What you'll learn on this episode:  The power of purpose-driven leadership The impact of values on team building and work focus How to connect individual impact to organizational goals The significant role of communication and active listening Strategies for continuous leadership development and growth The importance of authenticity, honesty, and integrity in leadership Additional Resources: William's LinkedIn  Agios Pharmaceuticals' Website >> https://agios.com/  Learn more about PK Deficiency >>  https://www.knowpkdeficiency.com/ Learn more about opportunities to work with Agios and search their open positions below: https://phe.tbe.taleo.net/phe03/ats/careers/v2/searchResults?org=AGIOS&cws=37 

Dr. Christina Rahm is a serial entrepreneur, author, scientist, and the CEO of DRC Ventures. With a robust background in pharmaceuticals and nutraceuticals, Christina has collaborated with industry leaders like Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. As Chief Science Officer for Root Brands, Dr. Rahm plays a pivotal role in shaping the industry and serves as a formulator for various companies under the DRC imprimatur, including Rahm Roast Coffee. Her book, "Cure the Causes: Live the Life you Want, Not the One Prescribed," reflects her dedication to holistic well-being. Christina is dedicated to eliminating negative influences and creating meaningful lives.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.This week's Commercialization Weekly highlights Bristol Myers' success with a Kras drug trial, Astrazeneca's FDA approval for a rare disease drug acquired from Alexion, FDA approval for Akebia's anemia pill after a previous rejection, and Acorda's bankruptcy filing. The FDA is also set to make decisions on expanding the use of two multiple myeloma cell therapies, a top-selling medicine, and Pfizer's gene therapy work. Risant Health has launched after Kaiser closed the acquisition of Geisinger, with plans to acquire more nonprofits. Surescripts is reportedly exploring a sale, with a private equity buyer being a potential option.Genmab acquired ProfoundBio for $1.8 billion, joining the trend of increased M&A activity in the development of antibody-drug conjugates. Paragon's hub-and-spoke biotech model resulted in another reverse merger with Oruka Therapeutics going public. Diagonal has raised $128 million to develop more efficient 'activator' antibody drugs. A dementia-focused venture capital firm is exploring new brain drugs beyond anti-amyloid therapies. Roivant reported positive immune drug data and announced share buyback plans.Genmab recently acquired the company ProfoundBio for $1.8 billion, expanding its presence in the antibody-drug conjugate (ADC) space with a focus on gynecologic cancers and solid tumors. Meanwhile, Diagonal Therapeutics secured $128 million in funding for their unique approach to developing agonist antibodies for rare diseases. In other news, Vanda Pharmaceuticals received FDA approval for their antipsychotic drug Fanapt for bipolar disorder, while Eli Lilly's diabetes treatment Mounjaro will be in short supply due to high demand.The text discusses the impact of tensions in U.S.-China research and development (R&D) relations on the Chinese antibody-drug conjugate (ADC) investment boom. With the departure of Chinese biotech company Wuxi from Bio, concerns over national security implications of U.S.-China R&D relationships are growing. The text also mentions the appointment of a new CEO at Lonza and Avenzo's pursuit of a licensing strategy with a new $150 million investment. Overall, the biopharma industry is experiencing significant developments in drug development, mergers and acquisitions, and regulatory decisions. Stay updated with Healthcare Dive for more insights into healthcare trends and news.Thank you for tuning in to Pharma and Biotech daily. Stay informed!

The healthcare industry is full of data - today, approximately 30 percent of the world's data volume is being generated by the healthcare industry. And, sharing of this data can help to improve patient care. When different organizations share data, they can work together to better understand diseases and develop more effective treatments for patients. In a study run by Accenture, 84 percent of patients who share their health data have had a positive experience sharing it, and only two percent of respondents have had a negative experience. But, most patients who do not believe they share their data today say it is because no one has asked them to share it.Join panelists Alex Simmonds, drug development innovation lead at Bristol Myers Squibb, Colleen D'Abbene, director of U.S. diagnostics at Alexion, Colin Gibbons, sales leader with diagnostic cardiology solutions at Philips, and McCay Barnes, senior digital health product leader at Optum for a discussion moderated by Ben Ferrara, director of growth and corporate strategy in health and life sciences at Accenture, for a deep dive into how patients feel about sharing data, what are the barriers to sharing data and potential areas ripe for innovation.For more information, visit matter.health and follow us on social: LinkedIn @MATTERTwitter @MATTERhealthInstagram @matterhealth

Dr. Christina Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman of International Science Nutrition Society and Chief Science Officer for ROOT Wellness. Dr. Rahm has also served as a formulator for several companies and manufacturing labs, including her own. She has created multiple provisional patents, proprietary formulas, and trade secrets in addition to authoring her first book, Cure the Causes: Live the Life you Want, Not the One Prescribed. Through years of laboratory research and ethical observations, she has developed a personalized and predictive consulting company working on everything from the environment to DNA and detox wellness plans in which Dr. Rahm helps clients reset their bodies and minds to be spiritually, mentally, emotionally, and physically balanced. ProtonMail Keep your conversations private. Proton Mail is an encrypted email service based in Switzerland.https://www.georgebatista.comProtonmail - Protonmail.georgebatista.comWellness Resources - http://www.myvitaminresource.com(Promocode: counterparts - For free shipping)https://www.instagram.com/georgebatistajr/rumble.georgebatista.comhttps://apple.co/3H39DGKEmail: Wellnesstalk@protonmail.com Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showDisclaimer: The Wellness Talk podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Jointly Provided by the American Academy of CME and CheckRare CE Support for this accredited continuing education activity has been made possible through an educational grant from Kyowa Kirin. Estimated time to complete: 0.50 hours Start date: November 30, 2023 End date: November 30, 2024 This 15-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose tumor induced osteomalacia (TIO) based on the recently published guidelines in the Journal of Internal Medicine. To earn credit, go to https://checkrare.com/learning/p-new-guidance-to-diagnose-and-treat-tumor-induced-osteomalacia-tio-2023-1/ Activity Faculty Aliya Khan MD, FRCPC, FACP, FACE, FASBMR Clinical Professor of Medicine Director, Calcium Disorders Clinic Director, Fellowship in Metabolic Bone Disease McMaster University Target Audience: This activity is designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management, and radiology, who may be involved in the care for individuals with TIO. Other healthcare providers may also take part. Learning Objectives: After participating in the activity, learners should be better able to • Describe the latest recommendations for diagnosing patients with TIO• Describe the latest recommendations for treating patients with TIO Accreditation and Credit Designation: In support of improving patient care, this activity has been planned and implemented by the American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other members of the care team will receive a certificate of participation. Disclosure Statement: According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Khan discloses the following relevant financial relationships with ineligible companies to disclose: • Advisory Board/Consultant: Amgen, Ascendis, Alexion • Grant/Research support: Ascendis, Alexion, Amolyt • Speakers Bureaus: Amgen, Ascendis, Alexion Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information. Method of Participation: There are no fees to participate in the activity. Participants must review the activity information, including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at: https://checkrare.com/learning/p-new-guidance-to-diagnose-and-treat-tumor-induced-osteomalacia-tio-2023-1/. Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ For any questions, please contact: CEServices@academycme.org Copyright © 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Jointly Provided by American Academy of CME and CheckRare CE Support for this accredited continuing education activity has been made possible through educational grant from Kyowa Kirin. Estimated time to complete: 0.25 hours Start date: November 30, 2023 End date: November 30, 2024 This 15-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose tumor induced osteomalacia (TIO) based on the recently published guidelines in the Journal of Internal Medicine. To earn credit, go to https://checkrare.com/learning/p-new-guidance-to-diagnose-tumor-induced-osteomalacia-tio-2023-2/Activity Faculty Aliya Khan MD, FRCPC, FACP, FACE, FASBMR Clinical Professor of Medicine Director, Calcium Disorders Clinic Director, Fellowship in Metabolic Bone Disease McMaster University Target Audience This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management, and radiology, who may be involved in the care for individuals with TIO. Other healthcare providers may also participate. Learning Objectives After participating in the activity, learners should be better able to • Describe the latest recommendations for diagnosing patients with TIOAccreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Khan discloses the following relevant financial relationships with ineligible companies to disclose: • Advisory Board/Consultant: Amgen, Ascendis, Alexion • Grant/Research support: Ascendis, Alexion, Amolyt • Speakers Bureaus: Amgen, Ascendis, Alexion Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at: https://checkrare.com/learning/p-new-guidance-to-diagnose-tumor-induced-osteomalacia-tio-2023-2/Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Jointly Provided by American Academy of CME and CheckRare CE Support for this accredited continuing education activity has been made possible through an educational grant from Kyowa Kirin. Estimated time to complete: 0.25 hours Start date: November 30, 2023 End date: November 30, 2024 This 15-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose tumor induced osteomalacia (TIO) based on the recently published guidelines in the Journal of Internal Medicine. To earn credit, go to https://checkrare.com/learning/p-new-guidance-to-treat-tumor-induced-osteomalacia-tio-2023-3/ Activity Faculty Aliya Khan MD, FRCPC, FACP, FACE, FASBMR Clinical Professor of Medicine Director, Calcium Disorders Clinic Director, Fellowship in Metabolic Bone Disease McMaster University Target Audience This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management, and radiology, who may be involved in the care for individuals with TIO. Other healthcare providers may also participate. Learning Objectives After participating in the activity, learners should be better able to • Describe the latest recommendations for treating patients with TIOAccreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Khan discloses the following relevant financial relationships with ineligible companies to disclose: • Advisory Board/Consultant: Amgen, Ascendis, Alexion • Grant/Research support: Ascendis, Alexion, Amolyt • Speakers Bureaus: Amgen, Ascendis, Alexion Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of Participation There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments at: https://checkrare.com/learning/p-new-guidance-to-treat-tumor-induced-osteomalacia-tio-2023-3/Your certificate will be emailed to you in within 30 days. Privacy For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ Contact For any questions, please contact: CEServices@academycme.org Copyright © 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: BMS buys Mirati; slow Q3 for biopharma M&A; Roche on its neuroscience strategy; Alexion talks about AstraZeneca integration; and Gilead on trial diversity. https://scrip.citeline.com/SC149190/Quick-Listen-Scrips-Five-MustKnow-Things

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.According to predictions from Evaluate Pharma, the outlook for big pharma's top companies is expected to shift in 2028. Roche, Merck & Co., and AbbVie are predicted to be at the top based on annual worldwide sales, while Pfizer and Johnson & Johnson are expected to drop down a few notches. Eli Lilly and Novo Nordisk are projected to enter the top 10 with their diabetes and weight loss earnings, pushing Bristol Myers Squibb and GSK out of the ranking. However, accurately predicting the successes and failures in the pharmaceutical industry is challenging.Moderna's recent five-year plan, which involves multiple launches and clinical programs for a company with only one product on the market, is explored as an example of a bold vision among pharma giants. The article also mentions that the market for cell and gene therapies is expected to grow from $9 billion in 2023 to over $42 billion by 2030.Novartis has decided to halt work on a gene therapy treatment for geographic atrophy following a review by a trial monitoring committee which concluded that the data did not support further development. The decision comes after Novartis acquired the therapy through its deal with Gyroscope Therapeutics. Meanwhile, Moderna has announced an ambitious drug development plan, stating that it expects to launch up to 15 new products in the next five years. This goal will require significant success in research and development efforts.Otsuka has partnered with Shape in a deal to design eye gene therapies using machine learning and high throughput screening. The partnership aims to identify new AAV capsids for gene therapies. Additionally, AstraZeneca's Alexion unit is partnering with genomics biotech Verge Genomics to gain access to its AI technology and platform. These partnerships and developments highlight the continued advancement and interest in gene therapy research and development.GoodRx has partnered with pharmacy benefit manager (PBM) MedImpact to increase access to its drug discount coupons. This is GoodRx's third partnership with a PBM. The collaboration aims to provide more affordable prescription medications to patients.A report from the Blue Cross Blue Shield Association (BCBSA) found a wide variety in medical costs depending on the site of care. The data supports site-neutral proposals that aim to make healthcare costs the same regardless of where they are provided. However, these proposals face opposition from hospitals.A majority of ground ambulance rides in 2022 were out-of-network, according to a report. Patients often have little choice in selecting an ambulance provider, and federal law does not protect them from surprise bills from these rides.Labor pressures for nonprofits in the healthcare sector are showing signs of easing. Job openings, employee departures, and wage growth have declined as health systems continue to add workers to their payroll.CVS CEO Karen Lynch expressed optimism that payers will improve Medicare Advantage (MA) star ratings. She also questioned the $500 million in savings that Blue Shield of California expects from ending its partnership with CVS' pharmacy benefit manager.The text discusses two main topics. The first is the potential scaled-back production of COVID-19 booster shots due to low demand. Last year, only 17% of the US population received the booster compared to 50% who received the initial jab, leading to declining sales for vaccine producers Moderna and Pfizer. If this trend continues, investment and manufacturing strategies may need to change.The second topic focuses on a marketing campaign by a large pharmaceutical company, Sanofi, to raise awareness about flu vaccinations, particularly among older and marginalized groups. The campaign features rapper and actor Ice-T in a spooky ad campaign highlighting the complications of the flu for these

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca has partnered with genomics biotech company Verge Genomics to gain access to its platform, which uses human tissue data to identify drug targets for nerve system diseases. This collaboration aims to help AstraZeneca's Alexion unit find new drug targets as it expands its pipeline. Advocates are pushing for increased funding for research into antimicrobial resistance, arguing that the proposed $6 billion in funding under the Pasteur Act is insufficient. They believe more needs to be done to combat antibiotic-resistant infections and develop better antibiotics.Roche's under-the-skin version of cancer immunotherapy drug Tecentriq has faced manufacturing delays in the US. The company will not be able to launch the subcutaneous formulation until 2024 as it works with the FDA on manufacturing updates.Otsuka has formed a partnership with Shape Therapeutics to develop gene therapies for eye diseases. Shape Therapeutics will use its machine learning and high throughput screening technologies to identify new adeno-associated virus capsids for gene therapies.Seagen has teamed up with Nurix to develop a new type of cancer drug. This alliance aims to combine Seagen's antibody expertise with Nurix's targeted protein degradation research. This partnership comes as Seagen awaits regulatory approval for its acquisition by Pfizer.CVS has announced a major corporate restructuring, appointing its CFO, Shawn Guertin, as the head of its suite of care delivery businesses. This move comes as CVS experiences declining profits.Medical credit cards are under scrutiny for exploiting loopholes in healthcare debt protection. These cards, often offered in hospitals and physician offices, can be deceptive and lead patients into significant medical debt.A report from the Kaiser Family Foundation (KFF) found that Medicare Advantage (MA) enrollment in rural areas has nearly quadrupled since 2010. However, these plans often have limited provider networks, posing challenges for beneficiaries who already have to travel long distances for care.Sanford Health, a nonprofit health system, has announced a shake-up in its C-suite. CEO Bill Gassen stated that the addition of new voices on the executive team will help the organization remain agile in the future.Walgreens has agreed to pay $44 million to settle claims over fraudulent blood tests conducted by Theranos. If approved by a judge, patients who purchased the tests will receive double the amount they paid plus additional compensation.Nationwide telehealth use remained steady in June, according to a report from Fair Health. Lawmakers have reintroduced legislation to make pandemic-era telehealth flexibilities permanent.The World Antimicrobial Resistance Congress celebrated a milestone in the fight against antibiotic-resistant infections with the FDA approval of Seres Therapeutics' microbiota-based therapy called VOWST for the prevention of recurrent Clostridium difficile. However, efforts to combat other antibiotic-resistant infections and provide sufficient funding through the Pasteur Act face challenges.Lundbeck CEO Dr. Deborah Dunsire shares insights on her recent wins and her favorite rule to break in a 5-minute interview. Gene therapy research is expected to revolutionize biopharma, with over 25 cell and gene therapy products already approved by the FDA.A poll asks whether the pharma industry's reputation is improving, with options for yes, no, and maybe. Last week's poll revealed that 60% of voters believe the drug pricing provisions in the Infrastructure Investment and Jobs Act will harm pharmaceutical R&D investments, while 30% disagreed and 10% were unsure.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more important news in the world of Pharma and Biotech.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. The Federal Trade Commission (FTC) has allowed Amgen's $28 billion acquisition of Horizon to proceed, with conditions. This settlement may ease concerns about regulatory hurdles for future deals in the industry. However, FDA documents suggest that Sage's depression drug, zurzuvae, may face challenges in obtaining broad approval due to concerns about side effects. On a positive note, Roche has claimed success in a study for its targeted lung cancer drug, Alecensa, with unprecedented results. This could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.In terms of investment, Julie Yoo from venture capital firm Andreessen Horowitz believes that the healthcare industry is at an inflection point and compared it to the internet era of 1999. Biotech mergers and acquisitions (M&A) activity is also picking up again, with Amgen's acquisition of Horizon set to become the largest industry deal since AstraZeneca's buyout of Alexion. Drug pricing in the US is also a trending topic, with launch prices steadily rising in certain therapeutic areas like cancer.Moving on to policy news, the Biden administration has proposed new nursing home staffing minimums to improve the quality of care in these facilities. Walgreens CEO Roz Brewer is stepping down and will be replaced by an executive with "deep healthcare experience." Amir Dan Rubin, CEO of One Medical, is also resigning from his position. The Office of the National Coordinator for Health Information Technology has chosen the Sequoia Project to oversee the Trusted Exchange Framework and Common Agreement (TEFCA) once again.In other updates, Roz Brewer's sudden departure from Walgreens has left many wondering about the reason behind it. Psycheceutical is developing a topical delivery technology for ketamine, which could have broader implications for other drugs. Ketamine has shown promise in treating mental health conditions such as treatment-resistant depression. J&J's Spravato, an FDA-approved drug for treatment-resistant depression, is administered nasally, but clinicians believe that intravenous ketamine is more effective. Psycheceutical aims to explore the potential relief provided by applying ketamine topically on the back of the neck.The rare disease market has seen significant growth in recent years, with pharmaceutical companies exploring treatments for these conditions. Ketamine's effectiveness in battling mental health conditions is being recognized, shifting its perception from a party drug to a potential therapeutic option. The text also mentions upcoming events and recent articles on various topics.In regulatory news, the FTC has given clearance for Amgen's acquisition of Horizon Therapeutics, subject to certain restrictions. Alvotech has resubmitted a Biologics License Application (BLA) to the FDA seeking an interchangeable designation for its biosimilar of Humira. Lawmakers have called on Lilly, Novo Nordisk, and Sanofi to provide details on their insulin assistance programs. Alkermes has settled a patent lawsuit with Teva over the generic version of Vivitrol. Biontech and DualityBio are moving their antibody-drug conjugate (ADC) into Phase III trials for HER2-low breast cancer.Lastly, Bayer has reported positive early data for a Parkinson's cell therapy treatment it acquired in 2019. Epigenic, a Chinese startup, has raised funds to use CRISPR tools to edit the epigenome and alter gene expression without changing DNA. Catalent, a contract development and manufacturing organization (CDMO), is expanding its board and setting up a committee to review its business and capital allocation priorities. Several biotech companies have made advancements in constructing small-molecule drugs to target RNA, revolutionizing the industry.These developments highlight significant activities in the p

Season 2 Episode 69 is here! The weekend is here and it brings along a new promo called Level Up. The gang will be joined by the one and only Alexion to discuss tactics and analyze if this new promo is a Level Up or Down. This is Nothin' But a FUT Thing!

There's no question that 2022 was a tumultuous year for biotech companies. As 2023 is underway, we're talking to Keith Woods, former COO and current strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on), a biotech company whose strong earnings come amid a downturn for the wider market and especially the biotech industry in 2022. While other companies continue to face challenges in this climate, this biotech is hitting its stride – argenx has managed rapid growth, and a successful drug launch.One major factor driving argenx's success: argenx's seasoned COO Keith Woods and his management philosophy of sustainable growth.https://www.argenx.com/ https://www.linkedin.com/in/keith-woods-5b8b67117/More about KeithKeith is was COO since 2018 and is currently a strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on). He comes with 25+ years of leadership experience in the biopharmaceutical industry, with the likes of Alexion, Roche, and Amgen. He has sage advice to offer about navigating market downturns, while still managing to grow and scale sustainably.**UPDATE** After recording this interview Keith transitioned from COO to Advisor on the argenx Board of Directors.  https://www.globenewswire.com/news-release/2023/03/02/2618906/0/en/argenx-Announces-Planned-Transition-of-Chief-Operating-Officer.html About argenxThe team at Argenx has created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies. We'll get more into their discoveries, culture, and how our listeners can bring about innovation by focusing more and more on patients.Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Have you ever wondered what the medical billing codes behind your healthcare bills were? How was your bill determined? Well, you're in luck! Our guest int his episode is Tamar Thompson, Avidity Bioscience Director and Vice President, Head of Corporate Affairs of Alexion, AstraZeneca Rare Disease, who is the expert on medical billing codes. Tamar talks about her journey toward her current position at Alexion and her insight on rare disease patient policy advocacy. Prior to her joining Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb and served as a strategic policy advisor for ADVI. Tamar has always been a driver toward helping patients through policy. Her work has been instrumental in informing rare disease patient advocacy and healthcare policies. Do you have any thoughts? Please email us at hello@rosenmaninstitute.org. We post new episodes every Monday. “The Health Technology Podcast” is produced by Herminio Neto, hosted by Christine Winoto, and engineered by Andrew John Rojek

Robyn Bolton is the Founder and Chief Navigator of MileZero, a consultancy that helps companies fuel innovation in their culture and products. As an expert in product strategy and innovation, she has worked with Nike, Nestlé, The Cable Center, Medtronic, Ariadne Labs, and Alexion, among many other leading names. Robyn's prior experience includes nearly a decade at Innosight, as Brand Manager at Proctor & Gamble, and as a consultant at Boston Consulting Group. Additionally, she has written for Forbes and Harvard Business Review and has been featured in The New York Times and NPR Marketplace. In this episode… Companies want their operations to be efficient, but they also want to be innovative industry leaders. Combining both these ideals can be challenging. Frequently innovation takes a back seat to the status quo of smooth operations. So how can leaders foster creative ideas within their organizations to stay ahead of the industry curve? This process is far easier said than done, with many converging reasons that keep innovation at bay. Great ideas are rarely given the proper consideration or the support they need to become something extraordinary. Robyn Bolton is an experienced consultant who has worked with countless leading brands, pointing them along the path toward innovation. According to Robyn, a lack of innovative ideas in your organization is due to a problem within the company's leadership. Leaders don't always realize that a culture that accepts new ideas doesn't exist within the company. In this episode of Next Wave Leadership, Robyn Bolton, the Founder and Chief Navigator at MileZero, returns to talk with Dov Pollack to break down innovation within the company structure and how it's a team sport. They touch on key leadership concepts and how they affect innovation, creating a culture that's conducive to fresh ideas, and why it's important to give accurate feedback early on in the process. Robyn also discusses essential questions that can create a positive impact throughout your company.

This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!At their base, the guidelines recommend intentional weight loss for higher-weight children via “Intensive Health Behavior and Lifestyle Training” starting as early as age two (2) with drugs as young as twelve (12) and surgeries starting as early as age thirteen (13).There is a lot to unpack here, and this will be a multi-part series but I have had a flood of requests to write about them since they came out, and I had to get very familiar with them because I presented Grand Rounds at Children's Minnesota this morning, so I thought I would get started with this first ever special edition of the newsletter so that I could get this info to you sooner and keep Saturday's newsletter from becoming a novel! I'm going to start with conflicts of interest because I believe these form the rickety scaffolding upon which the rest of these recommendations rest.When I think about conflicts of interest, I generally feel that having a conflict of interest is not proof of bias, but is certainly a red flag indicating the need for taking a deeper look. Failing to freely and openly disclose a conflict of interest, on the other hand, seems more to me like a red flag doused in gasoline and set on fire. There's a lot of the latter type of red flags in these guidelines.To address conflicts of interest, the guidelines themselves state:FINANCIAL/CONFLICT OF INTEREST DISCLOSURES: An Independent review for bias was completed by the American Academy of Pediatrics. Dr Barlow has disclosed a financial relationship with the Eunice Kennedy Shriver National Institute of Child Health and Human Development as a co-investigator.That's it. That is the only conflict of interest information provided. The same language is provided at the top of the guidelines and under the section “competing interests.” I cannot find any link to the actual review that they performed (if I missed it/you have it, please feel free to leave it in the comments!) I have to tell you that Dr. Barlow's disclosed relationship is pretty much the least of my concerns here.For example, based on their disclosure language you might not guess that, of the 14 authors who are medical doctors, at least 7 have taken money from companies that are developing or sell weight loss products that either directly benefit, or may benefit from these recommendations either through the development of a new drug, or approval of an existing drug for adolescents. The amount ranged from less than $20 for food and beverage (typically indicating that the doctor had attended one or more “educational” seminars by these companies,) to one author who took more than $50,000 primarily for consulting and speaking engagements on behalf of these companies.One of the companies that many took money from was Novo Nordisk, the pharmaceutical company which is aggressively marketing the drugs that are discussed in the guidelines (with an acknowledgment that they were included in the guidelines even though the research for them was published after the evidence review had already been completed.) Also, these numbers are only for 2015-2021 and where data is available. We know that Novo Nordisk has been pouring money into their effort to promote Wegovy and make good on their promise to shareholders that they would use the drug to double their “ob*sity* sales” by 2025, so it's possible that quite a bit more money has changed hands than is represented here. Regardless, as you can see, none of these payments are mentioned in the conflict of interest statement.Based on the American Academy of Pediatrics' conflict of interest statement, you also might not guess that, in fact, Novo Nordisk is a “Patron” of the American Academy of Pediatrics itself- donating somewhere between $25,000 and $49,999 to the organization.Other “patrons” of the AAP include:GlaxoSmithKline, maker of the weight loss drug alliGenentech, which sells the weight loss drug XenicalProlacta, which manufactures human milk-based nutritional products that they claim lowers the risk of ob*sityOf course, none of this is proof that they manipulated the guidelines to benefit these companies, but absolutely none of this is disclosed in the conflict of interest statement which, again…big red flag for me. Considering all of this, I am unconvinced that the American Academy of Pediatrics was in a position to conduct an “Independent review for bias” of guidelines that are incredibly favorable for their “patrons” and the companies from which the authors received money.You may also be surprised to learn that disclosure rules don't even require that they acknowledge that almost every author has a career that is based in the “higher-weight as lifelong chronic illness” model that these guidelines embrace and perpetuate. There are authors who run pediatric weight loss clinics, authors who run pediatric weight loss surgery programs, authors who are employed as pediatric weight management specialists. Below you'll find a list of the authors with information that I pulled from their various online bios about their past and current work in pediatric “ob*sity” as well as the payments I found to them on openpayments.cms.govFor almost all of the authors, these recommendations will increase the market for their services. That doesn't necessarily mean that's why they are making the recommendations, but it's still the literal definition of a conflict of interest. And yet, no disclosure of this is even required and, as you might imagine, none is made.There is also one oddity that I want to point out. Sarah C. Armstrong (who, of the authors who are MDs, took the most money from pharmaceutical companies that do or may benefit from these guidelines at $51,050.45) claims “I subscribe to a "health at every size" approach to supporting children, teens, and young adults living with ob*sity” on the same webpage on which her title is “Medical Weight Management Specialist.” That is, quite literally, impossible as those two things are mutually exclusive. Health at Every Size™ stands completely opposed to the concept of weight management and the pathologizing of body size, including the use of the term “ob*sity.” There is no ambiguity or grey area here, Health at Every Size™ is the trademarked brand of the Association for Size Diversity and Health, there are literally rules for this. So, from my perspective either Dr. Armstrong (a medical doctor who is co-authoring guidelines for other doctors) doesn't understand the basic principles upon which she claims her practice is built, or she is co-opting the language of weight-neutral health in order to promote weight loss. Either way, to me this is concerning enough to point out.I want to be clear, I don't think that these authors are necessarily trying to create profit for themselves, or to harm children. There are a LOT of degrees and certifications held by these authors, and many hold positions at prestigious universities and healthcare facilities. I think they are probably well-intentioned and truly believe that they are doing what's best for children. (As someone who is both queer and fat, I can imagine that if, a few decades ago, you had gotten together a group of doctors who had centered their careers on treating “homosexuality,” you would have gotten guidelines very much like this.) I also think that they are deeply misguided, and that's not surprising given the billions that the weight loss industry has poured into conflating health with weight and weight loss, including in the research, and the (mis) education of healthcare practitioners. Still, I believe that, if adopted, these guidelines will do massive harm. In Saturday's regular edition of Weight and Healthcare there is a deeper dive into the guidelines themselves. And a piece specifically about their eating disorders claims is here. Here is the author list with payments and info I found about their work within the body size as pathology paradigm (note that this is not an exhaustive list and includes past and present work)Sarah E Hampl * Novo Nordisk, $15.15* Pediatrics, Weight Management Sandra G Hassink* Director of the AAP Institute for Healthy Childhood Weight* Began the weight management clinic at Nemours/AI DuPont Children's Hospital in 1988* Has collaborated in basic research efforts to identify pathophysiologic mechanisms of ob*sity* Has lectured widely in the field of pediatric ob*sity* Authored A Parent's Guide to Childhood Ob*sity, Pediatric Ob*sity: Prevention, Intervention, and Treatment Strategies for Primary Care, and Clinical Guide to Pediatric Weight Management* Dedicates a significant portion of her time to advocacy and policy development on ob*sity prevention and treatment. * Served on the IOM committee on Accelerating Progress on Ob*sity Prevention and was an author on the Expert Recommendations for Ob*sityAsheley  C Skinner* Areas of expertise: Implementation Science, Health Services Research, Child Ob*sitySarah C. Armstrong * Genetech $41,250.45, Pfizer $5,000, Novo Nordisk $4,800 * Medical Weight Management SpecialistSarah E. Barlow * Echosens $94.89, Alexion 84.31, Abbvie $52.83, Ethicon 51.10, Novo Nordisk 32.27, Avanos $14.13* Oversees an integrated program in ob*sity care that spans community programs, primary healthcare and tertiary care.Christopher F. Bolling * Allergan 145.29, Tris Pharma $50.82, GlaxoSmithKline $45.82, Sanofi $44.71, Takeda $30.39, Astra Zeneca 23.87* Ob*sity Task Force Chair, KY Chapter, American Academy of PediatricsKimberly C. Avila Edwards* Co-founded the Texas Center for the Prevention and Treatment of Childhood Ob*sity at Dell Children's Medical Center in 2010 * On the steering committee for the Institute for a Healthy Childhood Weight from 2012-2016* Chaired the Ob*sity Committee of TPS (Texas Pediatric Society) from 2007 to 2011Ihuoma Eneli* Director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital* Oversees a comprehensive pediatric ob*sity center with activities that include advocacy, prevention, medical weight management and adolescent bariatric surgery* Directs the Primary Care Ob*sity Network (PCON) which provides ob*sity-related training, resources and community integration for 21 primary care practices in Central Ohio* Has particular interest in intervention research for pediatric ob*sity* Member of the National Academy of Sciences Roundtable on Ob*sity SolutionsRobin Hamre* Ob*sity prevention program team leader for the Centers for Disease Control and Prevention Madeline M. Joseph* Chief, Division of Pediatric Bariatrics University of Florida HealthDoug Lunsford* Lead Patient Principal Investigator, PCORnet Ob*sity Studymember of the Parent and Patient Leadership Team for the Healthy Weight Network* Co-founder of the Healthy Weight Community* Twitter Bio: Working to end childhood ob*sityEneida Mendonca* Biomedical Informatics expert, no link to ob*sity medicineMarc P. Michalsky * Novo Nordisk $13,576.47* Surgical Director for the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital* Serves as a clinical investigator on several National Institutes of Health (NIH)-sponsored research initiatives examining outcomes following surgical weight reduction in the severely ob*se adolescent population.* Dr. Michalsky's team currently performs gastric sleeve surgery, gastric bypass surgery, and adjustable gastric banding on severely ob*se adolescentsNazrat Mirza (Rhythm Pharmaceuticals $526.50, Novo Nordisk $64.54)* Medical Director, IDEAL Pediatric Weight Management ClinicEduardo R. Ochoa * Merck $3,868.16* Principle investigator for the Children's Health Watch Little Rock site at Arkansas Children's HospitalMona Sharifi* Studies the effectiveness, cost-effectiveness, and implementation of novel primary care-based interventions for childhood ob*sity* Yale School of Medicine Ob*sity Research Working GroupAmanda E. Staiano* Pennington Biomedical Research Center. Assistant Professor, Pediatric Ob*sity and Health Behavior Lab* Studies the best ways to target children and adolescents who are most at-risk for ob*sity and chronic disease, tailoring physical activity interventions to help these children and adolescents achieve a healthy weightAshley E. Weedn * Novo Nordisk $64.52* During residency, she trained at the University of California at San Francisco in pediatric weight management* Her clinical and research interests are in childhood ob*sity. * She leads several pediatric ob*sity projects* Serves as the Medical Director of the OU pediatric multidisciplinary weight management clinic* Co-chairs the Ob*sity Special Interest Group of the Academic Pediatric Association* Serves as a Childhood Ob*sity Advisor for the American Academy of Pediatrics* Founded and co-chairs the Ob*sity Committee through the Oklahoma Chapter of the American Academy of Pediatrics* Works with pediatricians across the state to address childhood ob*sity, including development of toolkits and webinars for primary care providers on childhood ob*sity assessment and management.     Susan K. Flinn* Writer/editor for hireJeanne Lindros* Manager, Ob*sity Initiatives, American Academy of Pediatrics* Co-presenter: Virtual reality-based training for motivational interviewing around childhood ob*sity – are pediatricians “game”?Kymika Okechukwu* Senior Manager, Evidence-Based Medicine Initiatives  - American Academy of PediatricsStay tuned for Saturday's deep dive into the guidelines!Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter and get special benefits! Click the Subscribe button below for details:Liked this piece? Share this piece:More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

In this episode of the Impostor Syndrome Files, we explore the “first-generation” experience in the workplace. Maybe that means you're the first in your family to go to college, or the first in your family to be born in the U.S., or the first in your family to shift from poverty to middle class. My guest this week, Carly Goldsmith, shares her first-generation story as we discuss the unique challenges we experience when assimilating to the workplace and striving to belong. About My GuestCarly Goldsmith brings over two decades of human resource, business and coaching experience to work for her clients. As a coach, she partners with senior and mid-level leaders to leverage their strengths to maximize personal engagement and impact created in their roles. She has a passion for working with individuals who identify as women and first-generation professionals. Compassionate and intuitive by nature, Carly's facilitation style is often described as engaging, insightful, and empowering.Carly has coached leaders and professionals across multiple industries throughout the US and globally. In addition to her coaching, she has designed and facilitated in-person and virtual workshops and leadership development programs. Most recently, Carly has worked with leaders, groups and teams at Deloitte, Amazon Robotics, Charles River Associates, Verve, Teradata, Mass General Brigham, Alexion, Verizon, CFGI, and Squarespace.  In addition, she has supported women leaders in Executive Education programs at Bentley University and the Prism Program offered by the 3D Leadership Group. She also is the co-founder of Velocity Quest for Women, a global virtual community offering members programs to equip them with the tools to generate momentum towards new possibilities in work and life.~Connect with Carly:https://www.linkedin.com/in/cgoldsmith/https://www.velocityquestforwomen.com/ ~Connect with Kim and The Impostor Syndrome Files:Join the free Impostor Syndrome Challenge:https://yourcareersuccess.com/impostor-syndrome-challenge/ Learn more about the Leading Humans discussion group:https://yourcareersuccess.com/leading-humans-discussion-group/Join the Slack channel to learn from, connect with and support other professionals: https://forms.gle/Ts4Vg4Nx4HDnTVUC6 Join the Facebook group:https://www.facebook.com/groups/leadinghumansSchedule time to speak with Kim Meninger directly about your questions/challenges: https://bookme.name/ExecCareer/strategy-session Connect on LinkedIn:https://www.linkedin.com/in/kimmeninger/ Websites:https://yourcareersuccess.comhttps://impostorsyndromefiles.com

Proposed federal and state policies to restrict coverage and access to biomedical innovations approved through the FDA's accelerated approval pathway are setting off alarms among rare disease advocates. That's because accelerated approvals are a vitally important pathway for faster, reliable drug development to meet the unmet needs of people with rare diseases. Vital Transformation completed a comprehensive impact assessment of these proposed changes and what they could mean for patients currently lacking treatments and future innovations. In this Vital Health Podcast, Duane Schulthess takes a deep dive into those findings, joined by Amanda Malakoff, the Executive Director of the Rare Disease Company Coalition and Lisa Feng, the Senior Director of Policy at Alexion, AstraZeneca Rare Disease. Topics of discussion include the detrimental impacts of radical changes to the use of surrogate endpoints, and the virtually nonexistent impacts of accelerated approved medicines on state Medicaid budgets.See omnystudio.com/listener for privacy information.

ONCE UPON A GENE - EPISODE 162 Your Career and Personal Life Collide - Senior Vice President, Head of Development and Safety of Alexion, AstraZeneca and Smith Magenis Rare Disease Dad Gianluca Pirozzi Gianluca Pirozzi is a dadvocate and Senior Vice President, Head of Development and Safety at Alexion, AstraZeneca. His daughter has Smith Magenis syndrome.  EPISODE HIGHLIGHTS What is your connection to rare disease and how does it connect with your work? My childhood best friend was diagnosed with a rare disease called Fanconi Anemia and he died at the age of 19. I saw the world through his eyes and I learned so much about life because of him. He is also the reason I studied medicine. Years later, my daughter was diagnosed with a rare disease called Smith Magenis. At the time I was in drug development and I changed my career to focus more on rare diseases. What role do caregivers play in the rare disease patient journey and is their advocacy essential? The caregiver plays a major role- they're the depository of knowledge and understanding of the disease. The caregiver best understands the impact of the disease on a patient's day-to-day life. Advocating through fundraising, organizing family conferences and participating in registries is important.  How has your perspective of pharma changed since becoming a rare dad? Being in the pharma business, I know how expensive it is to run clinical studies and clinical research. As a caregiver, I defend access for as many patients as possible, but I also know that without a return of investment, there would be no research that leads to advancement or development of rare disease medicine. What aspects of being a rare dad are you grateful for? I'm grateful for being reminded everyday of what is truly important in life. When I see the struggles my daughter has with simple things, she also has gratitude and happiness when she succeeds with simple things. What does it take to prepare for a family trip? We have to think steps in advance, thinking about what time we will travel so we are planning around my daughter's best time of day. We talk to the doctor about medicine to help her relax and sleep. We bring her special bed and medical stroller and call the airline ahead of time to accommodate. It's a complicated process and we plan for challenges the best we can, bearing in mind that we will also have beautiful memories and everyone will have a good time. TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/ Interested in advertising on Once Upon a Gene? Email advertising@bloodstreammedia.com for more information!

Episode 28: Meet Our Newest Podcast Host (Brian Arana-Madriz, PharmD)   We're excited to officially introduce you to the newest member of our IPhO Podcast team, Brian Arana-Madriz.    Brian is a Global Regulatory Affairs Fellow at Alexion, AstraZeneca Rare Disease, and an active member of the IPhO National Fellows Council! Join us as we get to know Brian and learn about his background, experiences, future plans for the podcast, and helpful advice for those who may be pursuing non-traditional pharmacy roles. Whether it's advice on networking effectively, choosing a functional area, planning for fellowship interviews, or sending out fellowship applications—Brian's got you covered.    A Special thank you to our episode sponsors, Northeastern University, and Saint Joseph's University Philadelphia College of Pharmacy.   Northeastern University: https://bouve.northeastern.edu/pharmacy/fellowships/   SJU: https://www.sju.edu/departments/pharmacy-practice/postgraduate-programs/fellowships

ONCE UPON A GENE - EPISODE 158 Medical Student - Urvi Gupta Joins the Global Genes Rare Compassion Program with Alexions Patient Advocacy Champion Wendy Erler Wendy Erler is passionate about the caregiver and patient voice being at the forefront of her work at Alexion Pharmaceuticals. Urvi Gupta is a second year medical student, working with the rare disease community to shape her professional path forward in the medical field. In this episode, I talk with Wendy Erler and Urvi Gupta about the Global Genes Rare Compassion Program.  EPISODE HIGHLIGHTS Wendy, can you tell us about yourself? I lead the patient advocacy team at Alexion, a pharmaceutical company focused on rare diseases. We work with physicians, patients, families and caregivers and my job is focused on elevating that partnership and bringing the patient and caregiver voice into everything we do.  Urvi, can you share how you became involved with the rare disease community? In a class called Clinical Correlation, we had a patient visit and they mentioned the Global Genes Rare Compassion Program, which matches up medical students with patients who have rare diseases to allow them to learn from each other. I've had three patient partners through that program and it's been amazing and inspiring to network with everyone in the rare disease community.  Urvi, how essential do you think it is to experience a true doctor-patient relationship already? So many patients say their course of treatment varies greatly based on how well their doctor listens to them. I think that's so important when it comes to rare diseases because it's not something you see often and when a patient presents a unique set of symptoms, they can't be brushed off. It's been helpful to experience and come to understand that the patient's perspective is the one that matters and what will help get a diagnosis.  Urvi, in what ways are you interested in raising awareness of the rare disease community? I would advise all medical students interested in rare disease to join the Global Genes Rare Compassion Program. There are a lot of other rare disease organizations always looking for help and there's likely a perspective you can offer.  LINKS & RESOURCES MENTIONED Global Genes Rare Compassion Program https://globalgenes.org/compassion/ Alexion Pharmaceuticals https://alexion.com/ Connor B. Judge Foundation https://www.connorbjudgefoundation.org/ CONNECT WITH WENDY & URVI Wendy Erler https://www.linkedin.com/in/wendyerler/ Urvi Gupta https://www.linkedin.com/in/urvigupta1/ TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/

Matt Hay was a sophomore in college when he began to have problems with his hearing. He soon learned his hearing loss was caused by tumors on his nerves and was diagnosed with the rare condition neurofibromatosis. As a result of the condition, which can cause tumors to grow on nerves throughout the body, Hay has had to undergo 20 surgeries, including one to remove a tumor that blocked 80 percent of his spinal fluid and caused him to lose the ability to walk for a time. His diagnosis started him on not only a personal journey to fight his condition, but on a professional one as well as he became a patient advocate. We spoke to Hay, U.S. Director of advocacy for NF1 at Alexion, about his own journey as someone living with a rare disease, neurofibromatosis, and how his experience led him to become a patient advocate within the biopharmaceutical industry.

Dr. Ben Edwards interviews Dr. Christina Rahm. Dr. Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion.  Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman […]

Ele tem 4 cidadanias, já trabalhou em 7 países diferentes e hoje é o Head da Área Terapêutica de Hematologia, Nefrologia e Neurologia na Alexion Internacional,  Astrazeneca.Rony Golczewski é um dos grandes líderes atuantes da indústria farmacêutica, falamos muito sobre liderar em diferentes países, culturas e quais as grandes dificuldades de uma vida fora do seu país de origem.Rony indicou o livro The Millionaire Fastlane e o seriado La Casa de Papel.Só aqui no Via Oral, o Podcast da Indústria Farmacêutica!

In this episode, Stan speaks with Wendy Erler about her involvement in the treatment of patients with rare genetic disorders. From her start in the pharmaceutical industry, to her involvement with every major platform of drug development, to her position as vice president and head of patient advocacy at Alexion; Ms. Erler has always ensured that a patient's voice is heard. Learn more about Wendy Erler on twitter @wendy_erler Please like and subscribe so that we can reach more potential patients and their family.

This accredited CME activity, led by Satheesh Chonat, MD, Assistant Professor at Emory University School of Medicine and hematologist-oncologist at the Pediatric Hematology Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, highlights the latest real world data focused on paroxysmal nocturnal hemoglobinuria (PNH). Dr Chonat also provides expert analysis of the data's clinical relevance for members of the care team to help them manage patients with PNH they may encounter with this rare condition. PNH is a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue. Supported by an educational grant from Alexion Pharmaceuticals, Inc. For complete activity information and to obtain CME credit, please go to https://checkrare.com/learning-center/courses/

Educational Objectives Examine challenges in current treatment options for seizure clusters, including efficacy and safety, and differentiating routes of administration Highlight considerations in treatment of seizure clusters, including addressing barriers to treatment and providing patient counseling to improve outcomes Faculty: Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM  Professor Departments of Pharmacotherapy & Outcomes Science and Neurosurgery Virginia Commonwealth University, Medical College of Virginia Richmond, Virginia Neurocritical Care Clinical Pharmacist Virginia Commonwealth University Health Richmond, Virginia Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Department of Defense Consultant: UCB, Chiesi, Marinus, Alexion, Ceribell Speakers Bureau: UCB, Chiesi Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-129-H01-P. The activity is available for CE credit through March 31, 2023. This activity is supported by an educational grant from Neurelis Inc. Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus. She is a Past President of the Neurocritical Care Society. Dr. Brophy's research interests include neuropharmacotherapy, traumatic brain injury, biomarkers, hemostasis, stroke, and status epilepticus. Learn more about your ad choices. Visit megaphone.fm/adchoices

Case closed on patents, Alzheimer's data, generic approvals, and expanded approvals.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlexion + ChugaiBiogenViatrisAbbVieAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

556: In this interview, Angela Yochem, the executive vice president and Chief Transformation & Digital Officer at Novant Health, and George Llado, the senior vice president and chief information officer of Alexion Pharmaceuticals, focus on the power of ecosystems. Angela discusses the importance of leveraging ecosystems to drive innovation at scale, and she shares the story of how Novant Health formed an “unconventional partnership” with Stewart-Haas to build ICU carts for overrun hospitals. Meanwhile, George discusses Alexion's strategy of cultivating relationships with startups and venture capital firms to accelerate innovation, as well as his approach to strategic planning.